TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 03/17/22

TFF Pharmaceuticals (NASDAQ:TFFP) is trading ~6% higher in the pre-market Thursday after announcing a research agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation, a non-profit within the U.S. military. The Cooperative Research a...

AUSTIN, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced today ...

AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced ...

AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced ...

TFF Pharmaceuticals (NASDAQ:TFFP) and Catalent (NYSE:CTLT) are collaborating on the testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF’ patented Thin Film Freezing technology. Under the agreement, Catalent will provide ...

Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technology Collaboration focused on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery Catal...

TFF Pharmaceuticals (TFFP +6.0%) said in vitro neutralization and viral replication assays suggested that its inhaled niclosamide product candidate completely inhibits viral replication of the Delta and Omicron variants of SARS-CoV-2. “Inhaled niclosamide’s demonstrabl...

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1 Safety and Pharmacokinetic Data of Inhaled Niclosamide by End of 1Q&#...

AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...

Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple Variants AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceu...